FDA standing of a peptide
get_fda_statusRead-onlyIdempotent
Whether a peptide or NAD+ is FDA approved, and where it stands for compounding (503A categories, HHS's October 2026 policy), quoted from FDA pages with the address and day each was read, plus how much it has been tested in people (PubMed and ClinicalTrials.gov counts, and the conditions its registered studies examine), the reports to the FDA naming it, and the FDA recalls and warning letters naming it, each counted daily.
Tool call template
Replace each placeholder with a value matching the input schema. Only required parameters are included; add optional parameters as needed.
{
"id": 1,
"jsonrpc": "2.0",
"method": "tools/call",
"params": {
"arguments": {
"compound": "<compound>"
},
"name": "get_fda_status"
}
}Input Schema
| Name | Required | Description | Default |
|---|---|---|---|
| compound | Yes | A peptide, NAD+ or a peptide stack, in any common spelling: "NAD+", "BPC-157", "sermorelin", "CJC-1295 / ipamorelin", "GHK-Cu", "Wolverine stack". |